M.D. Anderson Cancer Center: Melanoma trials

The registry lists 98 Melanoma studies with M.D. Anderson Cancer Center as lead sponsor. 20 are open to participants now and 25 have results posted.

Phase 1 45Phase 2 48Phase 3 1No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaNot yet recruitingNCT07511036Phase 2
• Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial MetastasesNot yet recruitingNCT07444606Phase 1
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2
• Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)RecruitingNCT06660420Phase 1
• Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFEDRecruitingNCT06548789Phase 2
• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingNCT05704647Phase 2
• High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver MalignanciesRecruitingNCT05053555Not applicable
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingNCT05026983Phase 2
• Quality of Life, Lifestyle, and Psychosocial Factors in Patients With MelanomaRecruitingNCT04778449
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsRecruitingNCT04771520Phase 2
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruitingNCT04751396
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruitingNCT04693377Not applicable
• Nodal Radiation Therapy for Sentinel Lymph Node Positive MelanomaRecruitingNCT04594187Phase 2
• Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 PandemicRecruitingNCT04474301
• Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsRecruitingNCT04038619Phase 1
• Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or MelanomaRecruitingNCT03941756Not applicable
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary MetastasesRecruitingNCT03093909Phase 1
• Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruitingNCT01772771
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedNCT04789668Phase 1/2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results posted
• APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaTerminatedNCT02706353Phase 1/2Results posted
• Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Intratumoral Injections of LL37 for MelanomaCompletedNCT02225366Phase 1/2Results posted
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02027935Phase 2Results posted
• Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaCompletedNCT01827111Phase 2Results posted
• Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaCompletedNCT01740557Phase 1/2Results posted
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF InhibitorCompletedNCT01619774Phase 2Results posted
• Doxycycline, Temozolomide and Ipilimumab in MelanomaTerminatedNCT01590082Phase 1/2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results posted
• High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCICompletedNCT01266603Phase 2Results posted
• Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal MelanomaTerminatedNCT01200342Phase 2Results posted
• Ipilimumab + Temozolomide in Metastatic MelanomaCompletedNCT01119508Phase 2Results posted
• Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2Results posted
• Phase II Study of Tesetaxel in Metastatic MelanomaCompletedNCT01064713Phase 2Results posted
• Tumor and Vaccine Site With a Toll Like Receptor (TLR) AgonistCompletedNCT00960752Phase 2Results posted
• Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma PatientsCompletedNCT00525031Phase 2Results posted
• Biochemotherapy With Temozolomide for Metastatic MelanomaTerminatedNCT00505635Phase 2Results posted
• Fibrin Melanoma Axillary Node Study in Patients With MelanomaCompletedNCT00504582Not applicableResults posted
• Palonosetron for Prevention of Biochemotherapy Induced Nausea and VomitingCompletedNCT00412425Phase 1/2Results posted
• Melanoma Vaccine With Peptides and LeuprolideCompletedNCT00254397Phase 2Results posted
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsActive, not recruitingNCT06237881Phase 1/2
• Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaActive, not recruitingNCT05470283Phase 1
• Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint InhibitorsActive, not recruitingNCT04990726
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving ImmunotherapyActive, not recruitingNCT04645680Phase 2
• Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingNCT04407247Phase 1/2
• Dietary Intervention in Patients with a History of MelanomaTerminatedNCT03950635Phase 1
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesActive, not recruitingNCT03175432Phase 2
• Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedNCT03131908Phase 1/2
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
• Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2
• Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaWithdrawnNCT02719015Phase 1/2
• Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
• Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesTerminatedNCT02668770Phase 1
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1
• Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationActive, not recruitingNCT02231775Phase 2
• Adoptive Therapy Using Antigen-Specific CD4 T-CellsWithdrawnNCT02210104Phase 1
• Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT01955460Phase 1
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the BrainCompletedNCT01904123Phase 1
• Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1
• Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain MetastasesActive, not recruitingNCT01644591Phase 2
• Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorCompletedNCT01603212Phase 1
• Aerosolized Aldesleukin in Treating Patients With Lung MetastasesActive, not recruitingNCT01590069Phase 1/2
• Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous BypassCompletedNCT01433302
• IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic MelanomaWithdrawnNCT01409187Phase 1/2
• IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
• Open-Label Study of TPI 287 for Patients With Metastatic MelanomaWithdrawnNCT01340729Phase 1/2
• Nuclear and Near-Infrared (NIR) Imaging in MelanomaCompletedNCT01295931Phase 1
• A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaTerminatedNCT01067066Phase 1
• Study of Weekly LOC-paclitaxel Injection for MelanomaTerminatedNCT01039844Phase 1
• Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma PatientsWithdrawnNCT01003626Not applicable
• Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic MelanomaCompletedNCT00970996Phase 1
• Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide VaccineCompletedNCT00861406Phase 1
• Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the LiverCompletedNCT00833807Phase 1
• PET-CT in the Management of Patients With Stage III or IV Metastatic MelanomaCompletedNCT00828126
• Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I PortionTerminatedNCT00791271Phase 1
• Taxotere/Temodar/Cisplatin Study in Melanoma PatientsCompletedNCT00527761Phase 1
• Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma PatientsCompletedNCT00527657Phase 1
• Melanoma Detection by Oblique-Incidence Optical SpectroscopyCompletedNCT00526032
• Melanoma Risk-Reduction Among Patients and Family MembersCompletedNCT00510302
• Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)Active, not recruitingNCT00508443Phase 1/2
• Sample Collection From Melanoma PatientsTerminatedNCT00507325
• Evaluating the Use of Fibrin Tissue Adhesive in Melanoma PatientsCompletedNCT00506311Not applicable
• Prospective Measurement of Post-Treatment LymphedemaCompletedNCT00495950
• Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic MelanomaCompletedNCT00412581Phase 1
• Targeted Intervention for Melanoma PreventionCompletedNCT00394134Not applicable
• Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid MelanomaCompletedNCT00386906Phase 1
• Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaActive, not recruitingNCT00338377Phase 2
• Imatinib Mesylate in Treating Patients With Metastatic MelanomaCompletedNCT00027586Phase 2
• Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaCompletedNCT00002882Phase 3